



10/18/99

A

jc594 U.S. PTO  
09/19/99

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b> <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>	Attorney Docket No.	0010-1045-0
	First Inventor or Application Identifier	Hiroshi IZUI, et al.
	Title	L-GLUTAMIC ACID PRODUCING BACTERIUM AND PROCESS FOR PRODUCING L-GLUTAMIC ACID

<b>APPLICATION ELEMENTS</b> <small>See MPEP chapter 600 concerning utility patent application contents</small>	<b>ADDRESS TO:</b> Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
<p>1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g. PTO/SB/17) (Submit an original and a duplicate for fee processing)</p> <p>2. <input checked="" type="checkbox"/> Specification Total Pages <b>34</b></p> <p>3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) Total Sheets <b>2</b></p> <p>4. <input checked="" type="checkbox"/> Oath or Declaration Total Pages <b>3</b></p> <p>a. <input checked="" type="checkbox"/> Newly executed (original)</p> <p>b. <input type="checkbox"/> Copy from a prior application (37 C.F.R. §1.63(d)) (for continuation/divisional with box 15 completed)</p> <p>i. <input type="checkbox"/></p> <p><b>DELETION OF INVENTOR(S)</b> Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §1.63(d)(2) and 1.33(b).</p> <p>5. <input type="checkbox"/> Incorporation By Reference (usable if box 4B is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4B, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p>	<b>ACCOMPANYING APPLICATION PARTS</b>
<p>6. <input type="checkbox"/> Assignment Papers (cover sheet &amp; document(s))</p> <p>7. <input type="checkbox"/> 37 C.F.R. §3.73(b) Statement <input type="checkbox"/> Power of Attorney (when there is an assignee)</p> <p>8. <input type="checkbox"/> English Translation Document (if applicable)</p> <p>9. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>10. <input type="checkbox"/> Preliminary Amendment</p> <p>11. <input checked="" type="checkbox"/> White Advance Serial No. Postcard</p> <p>12. <input type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application. Status still proper and desired.</p> <p>13. <input checked="" type="checkbox"/> Certified Copy of Priority Document(s) (1) (if foreign priority is claimed)</p> <p>14. <input checked="" type="checkbox"/> Other: Notice of Priority, Receipt of an Original Deposit of Microorganisms for the Purpose of Patent Procedure (FERM BP-6614, FERM BP-6615, FERM BP-6616, FERM BP-6617, and FERM BP-6660)</p>	
<p>15. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below:</p> <p><input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application no.: Prior application information: Examiner: Group Art Unit:</p>	
<p>16. Amend the specification by inserting before the first line the sentence:</p> <p><input type="checkbox"/> This application is a <input type="checkbox"/> Continuation <input type="checkbox"/> Division <input type="checkbox"/> Continuation-in-part (CIP) of application Serial No. Filed on</p> <p><input type="checkbox"/> This application claims priority of provisional application Serial No. Filed</p>	
<p><b>17. CORRESPONDENCE ADDRESS</b></p> <p>OBLON, SPIVAK, MCCLELLAND, MAIER &amp; NEUSTADT, P.C. FOURTH FLOOR 1755 JEFFERSON DAVIS HIGHWAY ARLINGTON, VIRGINIA 22202 (703) 413-3000 FACSIMILE: (703) 413-2220</p>	

Name:	Norman F. Oblon	Registration No.:	24,618
Signature:	<b>MARVIN J. SPIVAK</b> REGISTRATION NUMBER 24,913	Date:	10/18/99
Name:		Registration No.:	

L-GLUTAMIC ACID PRODUCING BACTERIUM AND PROCESS FOR  
PRODUCING L-GLUTAMIC ACID

Technical Field

5

The present invention relates to a new L-glutamic acid producing bacterium and a process for producing L-glutamic acid by a fermentation method using the same. L-glutamic acid is an important amino acid as a food,  
10 medicament or the like.

Background Art

Heretofore, L-glutamic acid has been produced by a  
15 fermentation method using mainly so-called a coryneform L-glutamic acid producing bacterium belonging to the genus *Brevibacterium*, *Corynebacterium* or *Microbacterium* or a variant thereof (Amino Acid Fermentation, Gakkai Shuppan Center, pp. 195-215, 1986). Known processes for  
20 producing L-glutamic acid by a fermentation method using other strains include one using a microorganism belonging to the of *Bacillus*, *Streptomyces* or *Penicillium* (U.S. Patent No. 3,220,929), one using a microorganism belonging to the genus *Pseudomonas*,

*Arthrobacter*, *Serratia* or *Candida* (U.S. Patent No. 3,563,857), one using a microorganism such as a bacterium belonging to the genus *Bacillus*, *Pseudomonas*, *Serratia* or *Aerobacter aerogenes* (currently *Enterobacter aerogenes*) (Examined Japanese Patent Publication No. 32-9393), one using a mutant of *Escherichia coli* (Japanese Laid-open Patent Application No. 5-244970) and the like.

The productivity of L-glutamic acid has been considerably improved by the breeding of the above microorganisms or the improvement of the production processes. To meet growing demand for L-glutamic acid, the development of a more inexpensive and efficient process for producing L-glutamic acid is desired.

In view of the above situation, the inventors of the present invention has investigated and studied microorganisms having L-glutamic acid productivity broadly. As a result, it has been found that a microorganism having high L-glutamic acid productivity can be obtained by increasing the activity of an enzyme which catalyzes the L-glutamic acid biosynthesis reaction (citrate synthase, phosphoenolpyruvate carboxylase, glutamate dehydrogenase) of a microorganism belonging to the genus *Enterobacter*, *Serratia*, *Klebsiella* or *Erwinia* (Japanese Laid-open Patent Application Nos. 10-224909 and 10-297129).

The inventors have also found that a microorganism

having high L-glutamic acid productivity is obtained by enhancing the activity of each of these enzymes by introducing a gene coding citrate synthase (hereinafter sometimes abbreviated as "CS") and phosphoenolpyruvate carboxylase derived from the genus *Escherichia* into a valine sensitive strain belonging to the genus *Escherichia* (WO 97/08294).

Meanwhile, it has been reported that the introduction of a gene (CS gene) coding citrate synthase derived from *Escherichia coli* or *Corynebacterium glutamicum* is effective in improving the L-glutamic acid productivity of *Corynebacterium* or *Brevibacterium* (Examined Japanese Patent Publication No. 7-121228). When these coryneform bacteria were used as a host, the introduction of a CS gene derived from *Corynebacterium glutamicum* of the same species as the host showed a slightly higher effect than the introduction of a CS gene derived from *Escherichia coli* but there was not seen a marked difference between them.

As described above, it has been known that a CS gene is introduced into various microorganisms to improve L-glutamic acid productivity. However, there has not been known an example where a CS gene derived from a coryneform bacterium is introduced into a

microorganism belonging to enterobacteria such as a bacterium belonging to the genus *Escherichia*.

### Summary of the Invention

5

It is an object of the present invention to find a new L-glutamic acid producing bacterium having L-glutamic acid productivity in order to develop an inexpensive and efficient process for producing L-glutamic acid.

The inventors of the present invention have bred enterobacteria by introducing a gene to improve their productivity of L-glutamic acid. Generally, it has been considered that a better effect is obtained by using a endogenous gene of a host or a gene derived from a microorganism which is a relative of the host than by introducing a heterogeneous gene when the host has a target gene for the breeding of a microorganism by gene amplification. However, the inventors of the present invention have found it much more effective, for enterobacteria, in improving the L-glutamic acid productivity of a microorganism to introduce a CS gene derived from a coryneform bacterium than to introduce a CS gene derived from a microorganism of the same species

as the enterobacteria. The present invention has been accomplished based on this finding.

That is, the present invention provides:

- (1) a microorganism belonging to enterobacteria and  
5 having L-glutamic acid productivity, into which a citrate synthase gene derived from a coryneform bacterium is introduced,
- (2) the microorganism of above (1) wherein the coryneform bacterium is *Brevibacterium lactofermentum*,
- 10 (3) the microorganism of (1) or (2) wherein the microorganism belonging to enterobacteria which a bacterium belonging to the genus *Enterobacter* or *Klebsiella*,
- (4) the microorganism of (3) wherein the bacterium  
15 belongs to *Enterobacter agromellans* or *Klebsiella planticola*, and
- (5) a process for producing L-glutamic acid comprising the steps of culturing the microorganism of any one of the above (1) to (4) in a liquid medium to produce and  
20 accumulate L-glutamic acid in the medium and collecting the L-glutamic acid from the medium.

Brief explanation of the Drawings

Fig. 1 shows the construction of a plasmid pMWCB having a *gltA* gene; and

Fig. 2 shows the construction of a plasmid having a *gltA* gene.

5

#### Detailed Description of the Invention

The present invention will be described in detail below.

10 <1> microorganism of the present invention

The microorganism belonging to enterobacteria of the present invention is not particularly limited if it belongs to enterobacteria which can be conferred or improved L-glutamic acid productivity by introducing a  
15 CS gene derived from a coryneform bacterium. The microorganism is exemplified by a bacterium belonging to the genus *Enterobacter*, *Klebsiella*, *Serratia*, *Erwinia*, *Pantoea* or *Escherichia*. Out of these, bacteria belonging to the genus *Enterobacter* or *Klebsiella* are  
20 preferred. Illustrative examples of the bacteria are described below but the microorganism of the present invention is not limited to these examples.

Examples of the microorganism belonging to the genus *Enterobacter* that can be used for the present

invention are listed below.

- Enterobacter agglomerans*
- Enterobacter aerogenes*
- Enterobacter amnigenus*
- 5 *Enterobacter asburiae*
- Enterobacter cloacae*
- Enterobacter dissolvens*
- Enterobacter gergoviae*
- Enterobacter hormaechei*
- 10 *Enterobacter intermedius*
- Enterobacter nimipressuralis*
- Enterobacter sakazakii*
- Enterobacter taylorae*

More preferably, those bacterial strains listed below can be mentioned:

- Enterobacter agglomerans* AJ13355
- Serratia liquefacience* ATCC 14460

The *Enterobacter agglomerans* AJ13355 was deposited at the National Institute of Bioscience and Human-  
 20 Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry on February 19, 1998, and received an accession number of FERM P-16644, and then transferred to an international deposit under the Budapest Treaty on January 11, 1999, and  
 25 received an accession number of FERM BP-6614. The *Enterobacter agglomerans* ATCC 12287, and the *Serratia liquefacience* ATCC 14460 can be distributed from ATCC.



The *Enterobacter agglomerans*. AJ13355 strain is a strain isolated from soil in Iwata-shi, Shizuoka, Japan.

Physiological properties of AJ13355 are as follows.

- (1) Gram stain: Negative
- 5 (2) Aerophobicity: Facultative anaerobe
- (3) Catalase: Positive
- (4) Oxidase: Negative
- (5) Nitrate reduction ability: Negative
- (6) Voges-Proskauer reaction: Positive
- 10 (7) Methyl Red test: Negative
- (8) Urease: Negative
- (9) Indole production: Positive
- (10) Motility: Present
- (11) Hydrogen sulfide production in TSI culture medium:  
15 Slightly active
- (12)  $\beta$ -Galactosidase: Positive
- (13) Sugar assimilability:
  - Arabinose: Positive
  - Sucrose: Positive
  - 20 Lactose: Positive
  - Xylose: Positive
  - Sorbitol: Positive
  - Inositol: Positive
  - Trehalose: Positive
  - 25 Maltose: Positive
  - Melibiose: Positive
  - Adonitol: Negative

Raffinose: Positive

Salicin: Negative

Melibiose: Positive

(14) Glycerose assimilability: Positive

5 (15) Organic acid assimilability:

Citric acid: Positive

Tartaric acid: Negative

Gluconic acid: Positive

Acetic acid: Positive

10 Malonic acid: Negative

(16) Arginine dehydratase: Negative

(17) Ornithine decarboxylase: Negative

(18) Lysine decarboxylase: Negative

(19) Phenylalanine deaminase: Negative

15 (20) Chromogenesis: Yellow

(21) Gelatin liquefaction ability: Positive

(22) Growth pH: Not good growth at pH 4, good growth at pH 4.5-7

(23) Growth temperature: Good growth at 25°C, good growth at 30°C, good growth at 37°C, growth is possible at 42°C, no growth at 45°C

From these bacteriological properties, AJ13355 is determined to be *Enterobacter agglomerans*.

Examples of the microorganism belonging to the genus *Klebsiella* that can be used for the present invention are listed below.

*Klebsiella planticola*

*Klebsiella terrigena*

More preferably, the examples of the microorganism include *Klebsiella planticola* AJ13399.

The *Klebsiella planticola* AJ13399 was deposited at  
5 the National Institute of Bioscience and Human-  
Technology, Agency of Industrial Science and Technology,  
Ministry of International Trade and Industry on February  
19, 1998, and received an accession number of FERM P-  
16646, and then transferred to an international deposit  
10 under the Budapest Treaty on January 11, 1999, and  
received an accession number of FERM BP-6616.

The *Klebsiella planticola* AJ13399 strain is a  
strain isolated from soil in Sapporo-shi, Hokkaido,  
Japan.

15       Physiological properties of AJ13399 are as follows.

- (1) Cell morphology: Rod-shaped
- (2) Motility: Absent
- (3) Spore formation: Absent
- (4) Colony morphology on LabM nutrient agar: Circular,  
20 smooth surface, cream in color, even, raised, and  
glistening
- (5) Glucose OF test: Positive for fermentability
- (6) Gram stain: Negative
- (7) Aerophobicity: Facultative anaerobe
- 25 (8) Catalase: Positive
- (9) Oxidase: Negative
- (10) Urease: Positive

- (11) Cytochrome oxidase: Negative
- (12)  $\beta$ -Galactosidase: Positive
- (13) Arginine dehydratase: Negative
- (14) Ornithine decarboxylase: Negative
- 5 (15) Lysine decarboxylase: Positive
- (16) Tryptophan deaminase: Negative
- (17) Voges-Proskauer reaction: Positive
- (18) Indole production: Positive
- (19) Hydrogen sulfide production in TSI culture medium:
- 10 Negative
- (20) Citric acid assimilability: Positive
- (21) m- Hydroxybenzene acid assimilability: Negative
- (22) Gelatin liquefaction ability: Negative
- (23) Production of acid from sugar
- 15       Glucose: Positive
- Mannitol: Positive
- Rhamnose: Positive
- Arabinose: Positive
- Sucrose: Positive
- 20       Sorbitol: Positive
- Inositol: Positive
- Melibiose: Positive
- Amygdalin: Positive
- Adonitol-peptone-water: Positive
- 25       Cellobiose-peptone-water: Positive
- Dulcitol-peptone-water: Negative
- Raffinose-peptone-water: Positive

(24) Growth temperature: Good growth at 37°C, no growth at 45°C

From these bacteriological properties, AJ13399 is determined to be *Klebsiella planticola*.

5        Examples of the microorganism belonging to the genus *Serratia* that can be used for the present invention are listed below.

*Serratia liquefacience*

*Serratia entomophila*

10       *Serratia ficaria*

*Serratia fonticola*

*Serratia grimesii*

*Serratia proteamaculans*

*Serratia odorifera*

15       *Serratia plymuthica*

*Serratia rubidaea*

More preferably, *Serratia liquefacience* ATCC 14460 may be exemplified. *Serratia liquefacience* ATCC 14460 can be distributed from ATCC.

20       Examples of the microorganism belonging to the genus *Erwinia* that can be used for the present invention are listed below.

*Erwinia herbicola* (now classified as *Pantoea agglomerans*)

25       *Erwinia ananas*

*Erwinia cacticida*

*Erwinia chrysanthemi*

*Erwinia mallotivora*

*Erwinia persicinus*

*Erwinia psidii*

*Erwinia quercina*

5 *Erwinia rhapontici*

*Erwinia rubrifaciens*

*Erwinia salicis*

*Erwinia uredovora*

More preferably, *Erwinia herbicola* IAM1595

10 (*Pantoea agglomerans* AJ2666) is exemplified. *Erwinia herbicola* IAM1595 can be distributed from the Institute of Molecular and Cellular Biosciences, the University of Tokyo. It should be noted that in the "Bergey's Manual of Determinative Bacteriology, ninth edition," *Erwinia*

15 *helbicola* is not described and microorganisms which have been classified as *Erwinia helbicola* are classified as *Pantoea agglomerans*. Microorganisms which have been classified as *Erwinia helbicola* are now classified as *Pantoea agglomerans*. Thus the microorganisms belonging

20 to genus *Erwinia* and the microorganisms belonging to the genus *Pantoea* are closely related to each other. Therefore, any of microorganisms belonging to the genus *Pantoea* can be used as well as the microorganisms belonging to the genus *Erwinia*. Such microorganisms

25 include *Pantoea agglomerans* and *Pantoea dispersa*. *Erwinia herbicola* IAM1595 is designated as *Pantoea agglomerans* AJ2666, and was deposited at the National

Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry on February 25, 1999 as an international deposition under the Budapest Treaty  
5 and received an accession number of FERM BP-6660.

Examples of the microorganism belonging to the genus *Escherichia* that can be used for the present invention include *Escherichia coli*.

More preferably, *Escherichia coli* having valine  
10 resitance, for example, the following strains may be exemplified.

*Escherichia coli* K-12 (ATCC10798)

*Escherichia coli* B (ATCC11303)

*Escherichia coli* W (ATCC9637)

15 *Escherichia coli* K-12 (ATCC10798), *Escherichia coli* B (ATCC11303) and *Escherichia coli* W (ATCC9637) can be distributed from ATCC.

It should be noted that, the sugar metabolism by bacteria belonging to the genera *Enterobacter*,  
20 *Klebsiella*, *Serratia*, *Erwinia*, *Pantoea* and *Escherichia* such as those mentioned above is achieved via the Embden-Meyerhof pathway, and pyruvic acid produced in that pathway is oxidized in the tricarboxylic acid cycle as for aerobic condition. L-glutamic acid is  
25 biosynthesized from  $\alpha$ -ketoglutaric acid which is an intermediate of the tricarboxylic acid cycle by GDH or glutamine synthetase/glutamate synthase. Thus, these

microorganisms share the same biosynthetic pathway for L-glutamic acid, and microorganisms mentioned above are encompassed within a single conception according to the present invention. Therefore, microorganisms belonging to the enteric bacteria other than species and strains mentioned above also fall within the scope of the present invention.

The microorganism of the present invention is a microorganism belonging to the enteric bacteria and having L-glutamic acid productivity. The term "having L-glutamic acid production ability" as herein used means to have ability for accumulating L-glutamic acid in culture medium during cultivation. This L-glutamic acid production ability may be either one possessed by a wild-type strain as its property, or one imparted or enhanced by breeding. Microorganism, which can be imparted L-glutamic acid productivity by being introduced *gltA* gene, may be also used. The microorganism belonging to the enteric bacteria and having the L-glutamic acid production ability include, for example, such microorganisms having increased activity of one or more enzymes catalyzing one or more reactions for the biosynthesis of L-glutamic acid, and such microorganisms having decreased activity of an enzyme catalyzing a reaction branching from the pathway for L-glutamic acid biosynthesis and producing a compound other than L-glutamic acid, or lacking the



activity. The microorganism further includes those having increased activity of one or more enzymes catalyzing one or more reactions for the biosynthesis of L-glutamic acid, and decreased activity of an enzyme catalyzing a reaction branching from the pathway for L-glutamic acid biosynthesis and producing a compound other than L-glutamic acid, or lacking the activity.

The "coryneform bacteria" which can be a source for *gltA* gene being introduced into the enteric bacteria includes bacteria having been hitherto classified into the genus *Brevibacterium* but united into the genus *Corynebacterium* at present (*Int. J. Syst. Bacteriol.*, 41, 255 (1981)), and include bacteria belonging to the genus *Brevibacterium* closely relative to the genus *Corynebacterium*. Examples of such coryneform L-glutamic acid-producing bacteria include the followings.

- Corynebacterium acetoacidophilum*
- Corynebacterium acetoglutamicum*
- Corynebacterium alkanolyticum*
- Corynebacterium callunae*
- Corynebacterium glutamicum*
- Corynebacterium lilium* (*Corynebacterium glutamicum*)
- Corynebacterium melassecola*
- Corynebacterium thermoaminogenes*
- Corynebacterium herculis*
- Brevibacterium divaricatum* (*Corynebacterium*

*glutamicum*)

*Brevibacterium flavum* (*Corynebacterium glutamicum*)

*Brevibacterium immariophilum*

*Brevibacterium lactofermentum* (*Corynebacterium*

5 *glutamicum*)

*Brevibacterium roseum*

*Brevibacterium saccharolyticum*

*Brevibacterium thiogenitalis*

*Brevibacterium album*

10 *Brevibacterium cerinum*

*Microbacterium ammoniaphilum*

Specifically, the following strains of these  
bacteria are exemplified:

*Corynebacterium acetoacidophilum* ATCC13870

15 *Corynebacterium acetoglutamicum* ATCC15806

*Corynebacterium alkanolyticum* ATCC21511

*Corynebacterium callunae* ATCC15991

*Corynebacterium glutamicum* ATCC13020, 13032, 13060

*Corynebacterium lilium* (*Corynebacterium*

20 *glutamicum*) ATCC15990

*Corynebacterium melassecola* ATCC17965

*Corynebacterium thermoaminogenes* AJ12340 (FERM BP-  
1539)

*Corynebacterium herculis* ATCC13868

25 *Brevibacterium divaricatum* (*Corynebacterium*  
*glutamicum*) ATCC14020

*Brevibacterium flavum* (*Corynebacterium glutamicum*)

ATCC13826; ATCC14067

*Brevibacterium immariophilum* ATCC14068

*Brevibacterium lactofermentum* (*Corynebacterium glutamicum*) ATCC13665, ATCC13869

5        *Brevibacterium roseum* ATCC13825

*Brevibacterium saccharolyticum* ATCC14066

*Brevibacterium thiogenitalis* ATCC19240

*Brevibacterium album* ATCC15111

*Brevibacterium cerinum* ATCC15112

10       *Microbacterium ammoniaphilum* ATCC15354

A *gltA* gene derived from a coryneform bacterium can be obtained by isolating a DNA fragment which complement auxotrophy of a bacterium lacking CS activity such as a mutant of a coryneform bacterium from the chromosome DNA of the coryneform bacterium. The nucleotide sequence of the *gltA* gene of the coryneform bacterium is made known (*Microbiology*, 140, 1817-1828 (1994)). Therefore the *gltA* gene can be obtained by PCR method using the chromosome DNA as a template and primers which are synthesized based on the nucleotide sequence. The primers are exemplified by oligonucleotides having nucleotide sequence shown in SEQ ID NOS: 1 and No. 2.

To introduce a CS gene derived from a coryneform bacterium into the microorganism belonging to enterobacteria, the CS gene may be cloned on an

appropriate plasmid and the above starting parent strain which serves as a host may be transformed with the obtained recombinant plasmid. The number of copies of the CS gene (hereinafter abbreviated as "*gltA* gene") in  
5 the cell of the transformant is increased with the result of enhancement of CS activity.

While the plasmid is not particularly limited so long as it can autonomously replicate in a microorganism belonging to the enteric bacteria, examples of the  
10 plasmid include, for example, pUC19, pUC18, pBR322, pHSG299, pHSG298, pHSG399, pHSG398, RSF1010, pMW119, pMW118, pMW219, pMW218 and the like. Other than these plasmids, phage DNA vectors can also be used.

The introduction of the *gltA* gene can be realized  
15 by making the *gltA* gene present on the chromosome DNA of the above starting parent strain which serves as a host, preferably in multiple copies. To introduce the *gltA* gene into the chromosome DNA of the microorganism belonging to enterobacteria in multiple copies, a  
20 sequence present in the chromosome DNA in multiple copies such as repetitive DNA or inverted repeat present at a terminal region of a transposable element can be used. Alternatively, the *gltA* gene may be introduced into the chromosome DNA in multiple copies by inserting

the *gltA* gene in a transposon and transposing the transposon. The number of copies of the *gltA* gene in the cell of the transformant increases, thereby enhancing CS activity.

5           Transformation may be performed in accordance with, for example, a method of D. A. Morrison (*Methods in Enzymology*, 68, 326 (1979)) or a method in which recipient cells are treated with calcium chloride to increase permeability for DNA (Mandel, M. and Higa, A.,  
10 *J. Mol. Biol.*, 53, 159 (1970)).

The *gltA* gene which is to be introduced may have a promoter suitable for the cell of a microorganism belonging to enterobacteria, such as *lac*, *trp*, or  $P_L$  in place of an inherent promotor of the *gltA* gene.

15           Techniques such as cloning of a gene, digestion and ligation of DNA and transformation method are described in *Molecular Cloning*, 2nd edition, Cold Spring Harbor Press (1989).

In the microorganism of the present invention, the  
20 activity of an enzyme which catalyzes the biosynthesis of L-glutamic acid other than CS may be enhancing in addition to the introduction of a *gltA* gene derived from a coryneform bacterium. Illustrative examples of the enzyme for catalyzing the biosynthesis of L-glutamic  
25 acid include glutamate dehydrogenase (GDH), glutamine

synthase, glutamate synthase, isocitrate dehydrogenase, aconitate hydratase, phosphoenolpyruvate carboxylase (PEPC), pyruvate dehydrogenase, pyruvate kinase, enolase, phosphoglyceromutase, phosphoglycerate kinase, 5 glyceraldehyde-3-phosphate dehydrogenase, triosephosphate isomerase, fructose bisphosphate aldolase, phosphofructokinase, glucose phosphate isomerase and the like.

The activity of an enzyme which catalyzes a 10 reaction for generating a compound other than L-glutamic acid by branching off from the biosynthetic pathway of L-glutamic acid may be decreased or lost. Illustrative examples of the enzyme which catalyzes a reaction for generating a compound other than L-glutamic acid by 15 branching off from the biosynthetic pathway of L-glutamic acid include  $\alpha$ -ketoglutarate dehydrogenase ( $\alpha$ KGDH), isocitrate lyase, phosphate acetyltransferase, acetate kinase, acetohydroximate synthase, acetolactate synthase, formate acetyltransferase, lactate 20 dehydrogenase, glutamate decarboxylase, 1-pyrroline dehydrogenase and the like. Out of these enzymes,  $\alpha$ KGDH is preferred.

The genes coding for PEPC and GDH can each be obtained from a chromosome DNA of the aforementioned

microorganisms by isolating a DNA fragment complementing auxotrophy of a variant strain lacking the PEPC or GDH activity. Alternatively, because the nucleotide sequences of these genes of bacteria of the genus

5 *Escherichia* or *Corynebacterium* have already been elucidated (*Biochemistry*, 22, 5243-5249 (1983); *J. Biochem.* 95, 909-916 (1984); *Gene*, 27, 193-199 (1984); *Mol. Gen. Genet.* 218, 330-339 (1989) and *Molecular Microbiology*, 6, 317-326 (1992)), the genes can be

10 obtained by PCR using a primer synthesized based on each of the elucidated nucleotide sequences, and the chromosome DNA as a template.

In order to obtain such decrease or absence of enzyme activity as mentioned above in a microorganism

15 belonging to the enteric bacteria, a mutation causing the decrease or absence of the enzyme activity can be introduced into a gene encoding the enzyme by a conventional mutagenesis technique or genetic engineering technique

20 Examples of the mutagenesis technique include, for example, the method utilizing irradiation of X-ray or ultraviolet light, the method utilizing treatment with a mutagenic agent such as N-methyl-N'-nitro-N-nitrosoguanidine and the like. The site of gene to

25 which a mutation is introduced may be a coding region encoding an enzyme protein, or an expression control region such as a promoter.

Examples of the genetic engineering technique include, for example, genetic recombination, genetic transduction, cell fusion and the like. For example, a drug resistance gene is inserted into a target gene to  
5 produce a functionally inactivated gene (disrupted gene). Then, this deletion type gene is introduced into a cell of a microorganism belonging to the enteric bacteria, and the target gene on a chromosome is replaced with the deletion type gene by homologous recombination (gene  
10 disruption).

Whether a microorganism has decreased activity of a target enzyme or lacks the activity, or degree of the decrease of the activity can be determined by measuring the enzyme activity of bacterial cell extract or  
15 purified fraction of a candidate strain, and comparing it with that of a wild-type strain. For example, the  $\alpha$ KGDH enzymatic activity can be measured by the method of Reed et al. (L.J. Reed and B.B. Mukherjee, Methods in Enzymology 1969, 13, p.55-61).

20 For some enzymes, a target mutant may be selected by phenotype of the mutant. For example, a mutant whose  $\alpha$ KGDH activity is lost or decreased cannot grow or has a large decrease in its growth rate in a minimal medium containing glucose or a minimal medium containing acetic  
25 acid or L-glutamic acid as the only carbon source. However, normal growth is made possible by adding succinic acid or L-lysine, L-methionine and



diaminopimelic acid to a minimal medium containing glucose under the same conditions. It is possible to carry out a screening for a mutant whose  $\alpha$ KGDH activity is lost or decreased using this phenomenon as an index.

5           A method for producing a *Brevibacterium lactofermentum* strain lacking the  $\alpha$ KGDH gene based on homogenous recombination is detailed in WO95/34672, and a similar method can be used for microorganisms belonging to the enteric bacteria.

10           Examples of the mutant strain that lack the  $\alpha$ KGDH activity or have decreased activity thereof obtained as described above are *Enterobacter agglomerans* AJ13356 and *Klebsiella planticola* AJ13410. The strains *Enterobacter agglomerans* AJ13356 and *Klebsiella planticola* AJ13410  
15           were deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry on February 19, 1998 as accession numbers of FERM P-16645 and FERM P-16647, and then transferred to  
20           international deposits under the Budapest Treaty on January 11, 1999, and received accession numbers of FERM BP-6615 and FERM BP-6617, respectively.

          L-Glutamic acid can be produced and accumulated in a liquid culture medium by culturing the microorganism  
25           belonging to the enteric bacteria and being introduced *gltA* gene derived from coryneform bacteria in the medium.

          The medium may be an ordinary nutrient medium

containing a carbon source, nitrogen source, and inorganic salts, as well as organic nutrients such as amino acids, vitamins and the like, as required. It can be a synthetic medium or a natural medium. Any carbon  
5 sources and nitrogen sources can be used for the culture medium so long as they can be utilized by the microorganism to be cultured.

The carbon source may be a saccharide such as glucose, glycerol, fructose, sucrose, maltose, mannose,  
10 galactose, starch hydrolysates, molasses and the like. Further, an organic acid such as acetic acid and citric acid may also be used alone or in combination with other carbon sources.

The nitrogen source may be ammonia, ammonium salts  
15 such as ammonium sulfate, ammonium carbonate, ammonium chloride, ammonium phosphate, and ammonium acetate, nitrates and the like.

As organic trace nutrients, amino acids, vitamins, fatty acids, nucleic acids, materials containing them  
20 such as peptone, casamino acid, yeast extract, and soybean protein decomposition products and the like are used, and when an auxotrophic variant which requires an amino acid or the like for its growth is used, it is necessary to complement the nutrient required.

25 As the inorganic salt, phosphates, magnesium salts, calcium salts, iron salts, manganese salts and the like are used.

As for the culture conditions, cultivation is performed under aerobic condition at a temperature of 20-42°C and a pH of 4-8. The cultivation can be continued for 10 hours to 4 days to accumulate a considerable amount of L-glutamic acid in the liquid culture medium.

After the completion of the cultivation, L-glutamic acid accumulated in the culture medium may be collected by a known method. For example, it can be isolated by a method comprising concentrating the medium after removing the cells to crystallize the product, ion exchange chromatography or the like.

According to the present invention, since a microorganism belonging to enterobacteria can be efficiently conferred L-glutamic acid productivity, it is assumed that higher productivity can be conferred on the microorganisms by conventionally known breeding techniques for coryneform L-glutamic acid producing bacteria. Studies on culture conditions and the like are expected to lead to the development of an inexpensive and efficient process for producing L-glutamic acid.

#### Best Mode for Carrying out the Invention

The present invention will be explained more specifically with reference to the following examples.

(1) Construction of plasmid having *gltA* gene

A plasmid having the *gltA* gene derived from *Brevibacterium lactofermentum* was constructed as follows. PCR was performed by using primers having the nucleotide sequences represented in SEQ ID NOS: 1 and 2 selected based on the nucleotide sequence of the *gltA* gene of *Corynebacterium glutamicum* (Microbiology, 1994, 140, 1817-1828), and a chromosome DNA of *Brevibacterium lactofermentum* ATCC 13869 as a template to afford a *gltA* gene fragment of about 3 kb. This fragment was inserted into the plasmid pHSG399 (purchased from Takara Shuzo) digested with *Sma*I to afford a plasmid pHSGCB (Figure 1). Then, the pHSGCB was digested with *Hind*III, and an excised *gltA* gene fragment of about 3 kb was inserted into the plasmid pMW218 (purchased from Nippon Gene) digested with *Hind*III to afford a plasmid pMWCB (Figure 1). Expression of the *gltA* gene by the resulting plasmid pMWCB was confirmed by determination of enzyme activity in the *Enterobacter agglomerans*. AJ13355 strain.

(2) Construction of plasmid having *gltA* gene derived from *E. coli*

As a control, a plasmid having *gltA* gene derived from *Escherichia coli* was constructed as follows. The plasmid pTWVC having the *gltA* gene derived from *Escherichia coli* (W097/08294) was digested with *Hind*III and *Eco*RI, and the resulting DNA fragment having the *gltA* gene was purified and collected, and introduced

into the HindIII-EcoRI site of the plasmid pMW219 to afford a plasmid pMWC (Figure 2). Expression of the *gltA* gene by the resulting plasmid pMWC was confirmed by determination of enzyme activity and complementation of  
 5 auxotrophic strain of *E. coli* lacking *gltA* gene.

(3) Introduction of *gltA* gene into *Enterobacter agglomerans* and *Klebsiella planticola* and production of L-glutamic acid

The strains *Enterobacter agglomerans* AJ13355 and  
 10 the *Klebsiella planticola* AJ13399 were transformed with pMWC or pMWCB. Each of the resulting transformants AJ13355/pMWC, AJ13355/pMWCB, AJ13399/pMWC and AJ13399/pMWCB and the parent strains were inoculated into 500 ml-volume flask containing 20 ml of culture  
 15 medium comprising 40 g/L glucose, 20 g/L ammonium sulfate, 0.5 g/L magnesium sulfate heptahydrate, 2 g/L potassium dihydrogenphosphate, 0.5 g/L sodium chloride, 0.25 g/L calcium chloride heptahydrate, 0.02 g/L ferrous sulfate heptahydrate, 0.02 g/L manganese sulfate  
 20 tetrahydrate, 0.72 mg/L zinc sulfate dihydrate, 0.64 mg/L copper sulfate pentahydrate, 0.72 mg/L cobalt chloride hexahydrate, 0.4 mg/L boric acid, 1.2 mg/L sodium molybdate dihydrate, 2 g/L yeast extract, and 30 g/L calcium carbonate, and cultured at 37°C for 15 hours  
 25 with shaking. After the cultivation was completed, L-glutamic acid accumulated in the culture medium and residual glucose were measured. The results are shown

in Table 1.

Bacterial strain	Accumulated amount of L-glutamic acid (g/L)	Residual amount of Glucose (g/L)
AJ13355	0	0
AJ13355/pMW C	0.01	6.0
AJ13355/pMW CB	0.78	28.5
AJ13399	0	0
AJ13399/pMW C	2.85	0
AJ13399/pMW CB	4.71	0

L-glutamic acid productivity was observed in both

5 *Enterobacter agromellans* AJ13355 and *Klebsiella*  
*planticola* AJ13399 by introducing a *gltA* gene. The  
 accumulation of L-glutamic acid is more marked when a  
*gltA* gene derived from *Brevibacterium lactofermentum* is  
 introduced than when a *gltA* gene derived from

10 *Escherichia coli* is introduced. A great amount of  
 glucose remains in the case of the AJ13355/pMWCB without  
 being consumed under the above conditions. When culture  
 is carried out until all glucose is consumed, it is  
 assumed that about 1.5 to 2 g/l of L-glutamic acid can

15 be accumulated.

There was not seen a marked difference in the copy  
 number of plasmid between AJ13355/pMWC and AJ13355/pMWCB,

and between AJ13399/pMWC and AJ13399/pMWCB.

## SEQUENCE LISTING

<110> IZUI, Hiroshi

MORIYA, Mika

HARA, yoshihiko

ITO, Hisao

<120> L-GLUTAMIC ACID PRODUCING BACTERIUM AND PROCESS FOR  
PRODUCING L-GLUTAMIC ACID

<130> OP892

<141> 1999- -

<150> JP 10-297350

<151> 1999-10-19

<160> 2

<170> PatentIn Ver. 2.0

<210> 1

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer



&lt;400&gt; 1

gtcgacaata gccygaatct gttctggctg

30

&lt;210&gt; 2

&lt;211&gt; 30

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: primer

&lt;400&gt; 2

aagcttatcg acgctccct cccacggt

30

What is claimed is:

1. A microorganism belonging to enterobacteria and having L-glutamic acid productivity, into which a citrate synthase gene derived from a coryneform bacterium is introduced.
2. The microorganism of claim 1 wherein the coryneform bacterium is *Brevibacterium lactofermentum*.
3. The microorganism of any one of claims 1 or 2 wherein the microorganism belonging to enterobacteria which a bacterium belonging to the genus *Enterobacter* or *Klebsiella*.
4. The microorganism of claim 3 wherein the bacterium belongs to *Enterobacter agromellans* or *Klebsiella planticola*.
5. A process for producing L-glutamic acid comprising the steps of culturing the microorganism of any one of the claims 1 to 4 in a liquid medium to produce and accumulate L-glutamic acid in the medium and collecting the L-glutamic acid from the medium.

## Abstract

L-glutamic acid is produced by culturing in a medium a microorganism belonging to enterobacteria and  
5 having L-glutamic acid productivity, into which a citrate synthase gene derived from a coryneform bacterium is introduced to produce and accumulate L-glutamic acid in the medium and collecting the L-glutamic acid from the medium.

Fig.1





Fig.2



H i ; H i n d I I I  
 P ; P s t I  
 E ; E c o R I

# Declaration, Power Of Attorney and Petition

Page 1 of 3

WE (I) the undersigned inventor(s), hereby declare(s) that:

My residence, post office address and citizenship are as stated below next to my name,

We (I) believe that we are (I am) the original, first, and joint (sole) inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled

L-GLUTAMIC ACID PRODUCING BACTERIUM AND PROCESS FOR PRODUCING L-GLUTAMIC ACID

the specification of which

☒ is attached hereto.

☐ was filed on \_\_\_\_\_ as

Application Serial No. \_\_\_\_\_

and amended on \_\_\_\_\_

☐ was filed as PCT international application

Number \_\_\_\_\_

on \_\_\_\_\_

and was amended under PCT Article 19

on \_\_\_\_\_ (if applicable).

We (I) hereby state that we (I) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We (I) acknowledge the duty to disclose information known to be material to the patentability of this application as defined in Section 1.56 of Title 37 Code of Federal Regulations.

We (I) hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed. Prior Foreign Application(s)

Application No.	Country	Day/Month/Year	Priority Claimed
10-297350	Japan	19/10/1998.	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No

We (I) hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

_____ (Application Number)	_____ (Filing Date)
_____ (Application Number)	_____ (Filing Date)

We (I) hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.	Filing Date	Status (pending, patented, abandoned)
_____	_____	_____
_____	_____	_____
_____	_____	_____

And we (I) hereby appoint: Norman F. Oblon, Registration Number 24,618; Marvin J. Spivak, Registration Number 24,913; C. Irvin McClelland, Registration Number 21,124; Gregory J. Maier, Registration Number 25,599; Arthur I. Neustadt, Registration Number 24,854; Richard D. Kelly, Registration Number 27,757; James D. Hamilton, Registration Number 28,421; Eckhard H. Kuesters, Registration Number 28,870; Robert T. Pous, Registration Number 29,099; Charles L. Gholz, Registration Number 26,395; Vincent J. Sunderdick, Registration Number 29,004; William E. Beaumont, Registration Number 30,996; Steven B. Kelber, Registration Number 30,073; Robert F. Gnuse, Registration Number 27,295; Jean-Paul Lavalleye, Registration Number 31,451; Timothy R. Schwartz, Registration Number 32,171; Stephen G. Baxter, Registration Number 32,884; Martin M. Zoltick, Registration Number 35,745; Robert W. Hahl, Registration Number 33,893; Richard L. Treanor, Registration Number 36,379; Steven P. Weihrouch, Registration Number 32,829; John T. Goolkasian, Registration Number 26,142; Marc R. Labgold, Registration Number 34,651; William J. Healey, Registration Number 36,160; and Richard L. Chinn, Registration Number 34,305; our (my) attorneys, with full powers of substitution and revocation, to prosecute this application and to transact all business in the Patent Office connected therewith; and we (I) hereby request that all correspondence regarding this application be sent to the firm of OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C., whose Post Office Address is: Fourth Floor, 1755 Jefferson Davis Highway, Arlington, Virginia 22202.

We (I) declare that all statements made herein of our (my) own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Hiroshi IZUI  
NAME OF FIRST SOLE INVENTOR

Residence: Kawasaki-shi, Kanagawa, Japan

Hiroshi Izui  
Signature of Inventor

Citizen of: Japan  
Post Office Address: c/o Ajinomoto Co., Inc.,  
Fermentation & Biotechnology Laboratories,  
1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi,  
Kanagawa, Japan

October 6, 1999  
Date

Mika MORIYA

NAME OF SECOND JOINT INVENTOR

Residence: Kawasaki-shi, Kanagawa, Japan

Mika Moriya  
Signature of Inventor

Citizen of: Japan

Post Office Address: c/o Ajinomoto Co., Inc.,  
Fermentation & Biotechnology Laboratories,  
1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi,  
Kanagawa, Japan

October 6, 1999  
Date

Yoshihiko HARA

NAME OF THIRD JOINT INVENTOR

Residence: Kawasaki-shi, Kanagawa, Japan

Yoshihiko Hara  
Signature of Inventor

Citizen of: Japan

Post Office Address: c/o Ajinomoto Co., Inc.,  
Fermentation & Biotechnology Laboratories,  
1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi,  
Kanagawa, Japan

October 6, 1999  
Date

Hisao ITO

NAME OF FOURTH JOINT INVENTOR

Residence: Kawasaki-shi, Kanagawa, Japan

Hisao Ito  
Signature of Inventor

Citizen of: Japan

Post Office Address: c/o Ajinomoto Co., Inc.,  
Fermentation & Biotechnology Laboratories,  
1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi,  
Kanagawa, Japan

October 6, 1999  
Date

NAME OF FIFTH JOINT INVENTOR

Residence: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

Signature of Inventor

Citizen of: \_\_\_\_\_

Post Office Address: \_\_\_\_\_

\_\_\_\_\_

Date